70
Participants
Start Date
April 24, 2017
Primary Completion Date
August 17, 2021
Study Completion Date
August 17, 2021
Apremilast
Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.
Buffalo Medical Group, P.C., Buffalo
The University of Pennsylvania, Philadelphia
Dermatology and Skin Surgery Center, Exton
Derm Associates, P.C., Rockville
Center for Clinical Studies, Houston
University of Southern California, Los Angeles
Oregon Medical Research Center, Portland
Collaborators (1)
Celgene Corporation
INDUSTRY
National Heart, Lung, and Blood Institute (NHLBI)
NIH
University of Pennsylvania
OTHER